Evidence map›Paper›PMID 40159283›Full record

ArticleJournal of clinical and experimental hematopathology : JCEH2025

ALK-negative anaplastic large cell lymphoma with TP53 mutation developing during the administration of baricitinib for atopic dermatitis - A case report.

Hidetsugu Kawai, Shino Iwata, Sawako Shiraiwa, Masashi Miyaoka, Daisuke Ogiya, Masako Toyosaki, Shinichiro Machida, Rikio Suzuki, Makoto Onizuka, Yoshiaki Ogawa and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and experimental hematopathology : JCEH, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hidetsugu KawaiDepartment of Hematology / Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Shino IwataDepartment of Hematology / Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Sawako ShiraiwaDepartment of Hematology / Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Masashi MiyaokaDepartment of Pathology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Daisuke OgiyaDepartment of Hematology / Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Masako ToyosakiDepartment of Hematology / Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Shinichiro MachidaDepartment of Hematology / Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Rikio SuzukiDepartment of Hematology / Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Makoto OnizukaDepartment of Hematology / Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Yoshiaki OgawaDepartment of Hematology / Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Naoya NakamuraDepartment of Pathology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Hiroshi KawadaDepartment of Hematology / Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe atopic dermatitis (AD) is known to be associated with a risk of lymphoma. We herein report a case of ALK-negative anaplastic large cell lymphoma (ALK-ALCL) complicated by severe AD during treatment with baricitinib, which is an oral, selective, and reversible Janus Kinase (JAK) 1 and 2 inhibitor used in the treatment of AD. Next-generation sequencing (NGS) demonstrated the TP53 p.G266E mutation, suggesting that this was the trigger of the disease and the cause of its refractory course. The JAK/signal transducer and activator of transcription (STAT) pathway is often activated in tumor cells of ALCLs, suggesting that it is a therapeutic target. The causal connection between baricitinib and lymphomagenesis remains unknown; however, this patient developed ALK-ALCL with TP53 mutations during baricitinib treatment.

Indexed as

AzetidinesDermatitis, AtopicLymphoma, Large-Cell, AnaplasticMutationPyrazolesSulfonamidesTumor Suppressor Protein p53Anaplastic Lymphoma KinaseHumansPurinesALK protein, humanAnaplastic Lymphoma KinaseAzetidinesbaricitinibPurinesPyrazolesSulfonamidesTP53 protein, humanTumor Suppressor Protein p53ALK-negative anaplastic large cell lymphomaatopic dermatitisbaricitinibTP53 mutation

Identifiers

PMID40159283
PMCPMC12051419

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.